CD19 and acute lymphoblastic leukemia: reported that a second‐generation anti‐CD19 CAR containing 4‐1BB costimulatory domain (scFv‐CD8TM‐4‐1BB‐CD3ζ), which overcame inhibitory signals and induced NK cell specific killing of CD19+ acute lymphoblastic leukemia.